Oxygen Double Bonded And Nitrogen Bonded Directly To The Same Carbon Patents (Class 536/53)
  • Patent number: 10836834
    Abstract: Provided is a complex obtained by reacting a polymer compound derivative obtained by modifying part of the hydroxy groups or amino groups of a polymer compound having the hydroxy groups or amino groups with a compound represented by the following general formula (I) with one or more kinds of compounds represented by the following general formulae (II) to (V): (I) A-X—Si(Y)nR3-n; (II) M(OR1)nR24-n; (III) Al(OR1)pR23-p; (IV) Mg(OR1)qR22-q; and (V) [Si(OR3)nR43-n]—(X)—[Si(OR5)nR63-n].
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 17, 2020
    Assignee: DAICEL CORPORATION
    Inventors: Yoshio Okamoto, Chiyo Yamamoto, Tomoyuki Ikai, Masami Kamigaito
  • Patent number: 10745432
    Abstract: An object of the present invention is to provide a crystal of 6?-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a production process thereof. The present invention relates to a crystal of 6SL sodium salt and a process for producing the crystal.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 18, 2020
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Masahiro Abe, Tomoya Yokoi, Sotaro Sanpei, Kazunari Fukumoto, Hiroshi Nagano
  • Patent number: 10640578
    Abstract: The present invention generally relates to a modified hyaluronic acid (HA) and to a method for making same, more specifically to a (poly)glycerol-modified HA derivative prepared by grafting glycidol to HA. The present invention also relates to the use of the HA derivative for preparing a dermal filler composition, a hydrogel comprising cross-linked HA and the (poly)glycerol-modified HA derivative, and a method for preparing said hydrogel. Furthermore, the present invention relates to the use of the hydrogel as a cosmetic and/or aesthetic product, in particular as a dermal filler for tissue filling, replacing and/or augmenting.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 5, 2020
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Andreas Krause, Alexander Linko, Franck Villain
  • Patent number: 10463595
    Abstract: The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 5, 2019
    Assignee: ALLERGAN HOLDINGS FRANCE S.A.S.
    Inventors: Geoffrey C. Gurtner, Kenneth N. Horne, Jayakumar Rajadas
  • Patent number: 10024795
    Abstract: Provided is a method of monitoring a vesicle in a sample, including contacting a vesicle in a sample with a membrane permeable marker that is converted into a detectable marker in the vesicle, measuring a signal of the detectable marker, and monitoring the vesicle based on the measured signal.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 17, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyun-ju Kang, Ye-ryoung Yong, Myo-yong Lee
  • Patent number: 9718947
    Abstract: A process for the preparation of a chondroitin sulphate salt with an average molecular weight (Mw) of 10-30 kDa via chemical sulphation of an unsulphated chondroitin backbone is provided. The unsulphated chondroitin can be obtained by acid hydrolysis of a capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4 or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: August 1, 2017
    Assignee: Gnosis S.p.A.
    Inventors: Davide Bianchi, Marco Valetti, Paola Bazza, Nicolò Miraglia, Ermanno Valoti
  • Patent number: 9717754
    Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 1, 2017
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
  • Patent number: 9597675
    Abstract: An oxidation catalyst includes a support including particles of an alkaline earth salt, and first particles including a palladium compound on the support. The oxidation catalyst can also include precious metal group (PMG) metal particles in addition to the first particles intermixed together on the support. A gas permeable polymer that provides a continuous phase can completely encapsulate the particles and the support. The oxidation catalyst may be used as a gas sensor, where the first particles are chemochromic particles.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: March 21, 2017
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Nahid Mohajeri
  • Patent number: 9585987
    Abstract: A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes: a) a formulation containing a hyluronan (HA-formulation) which includes a hyaluronan backbone (HA backbone) and a plurality of a reactive substituent group (reactive HA substituent) which i) is directly attached to the HA backbone, and ii) exhibits the reactive HA-group, and b) a formulation of a homo-multifunctional cross-linking reagent (CLR-formulation) exhibiting a plurality of a reactive group (reactive CLR-group). The two reactive groups are selected as a pair of counterparts that mutually and selectively react with each other to form a linkage structure. The hydrogel contains a cross-linking structure which a) is attached to the hyaluronan via two or more of the linkage structure and is defined by the reagent. The cross-linking structure exhibits a plurality of hydroxyl groups. The composition can be used in vivo or ex vivo as a support matrix.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: March 7, 2017
    Assignee: PVAC MEDICAL TECHNOLOGIES LTD
    Inventors: Kristoffer Bergman, Tim Bowden, Thomas Engstrand, Jons Hilborn, Dmitri Ossipov
  • Patent number: 9567447
    Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: February 14, 2017
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Susan P. James, Min Zhang, Guy Beauregard
  • Patent number: 9556467
    Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 31, 2017
    Assignee: Garnet Bio Therapeutics, Inc.
    Inventors: Vanessa Ragaglia, Vandana Madanlal Sharma
  • Patent number: 9554987
    Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 31, 2017
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9533077
    Abstract: The present disclosure provides, inter alia, a method of producing an outer layer material for forming into a structure and that comprises an entanglement having a hydrophobic polymer host and a hydrophilic guest, including in one embodiment the steps of: intermingling cloaked hydrophilic guest complexes with the hydrophobic host; crosslinking molecules of the guest with the guest; and performing a hydrolysis reaction.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 3, 2017
    Assignee: Colorado State University Research Foundation
    Inventors: Susan P. James, Min Zhang, Guy Beauregard, Rachael Kurkowski Oldinski
  • Patent number: 9511015
    Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: December 6, 2016
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9371352
    Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 21, 2016
    Assignees: VACCINEX, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Steven A. Porcelli, Maurice Zauderer
  • Patent number: 9161945
    Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: October 20, 2015
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Fumiyasu Shiozawa, Yuki Iwata, Takahiro Oi, Kenichi Kawabe
  • Patent number: 9107882
    Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: August 18, 2015
    Assignee: PERNIX THERAPEUTICS HOLDINGS, INC.
    Inventor: Robert Lewis
  • Patent number: 9067960
    Abstract: Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: June 30, 2015
    Assignee: The Johns Hopkins University
    Inventors: Kevin J. Yarema, Udayanath Aich, Christopher T. Campbell, Srinivasa-Gopalan Sampathkumar, Sean S. Choi, Michael A. Meledeo, Christopher Weier
  • Patent number: 9051592
    Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 9, 2015
    Assignee: Garnet Biotherapeutics, Inc.
    Inventors: Vanessa Ragaglia, Vandana Madanlal Sharma
  • Publication number: 20150148310
    Abstract: The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventor: Glenn Prestwich
  • Patent number: 9034844
    Abstract: The present invention relates to a process of synthesis of ?-sialyl oligosaccharides and in particular of 6?-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: May 19, 2015
    Assignee: INALCO S.P.A.
    Inventors: Giancarlo Tamerlani, Ilaria Lombardi, Debora Bartalucci, Andrea Danesi, Liana Salsini, Marco Manoni, Giovanni Cipolletti
  • Publication number: 20150126727
    Abstract: The present invention provides a method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells comprising the step: extracting LPS from the cell culture in a composition (LPS extraction composition) comprising water, an alcohol and a further organic solvent.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Philippe CHARLES, Geoffroy GELDHOF, Vincent MANCUSO
  • Publication number: 20150126468
    Abstract: A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.
    Type: Application
    Filed: August 22, 2011
    Publication date: May 7, 2015
    Inventors: Sunil Shaunak, Ian Alfred Teo
  • Patent number: 9023830
    Abstract: There is disclosed a cosmetic comprises a sugar compound obtained by reacting a hydroxyl group of a saccharide, an isocyanate group-containing organopolysiloxane represented by the following general formula (1), and an isocyanate group-containing organic compound represented by the following general formula (2). As a result, there is provided a cosmetic excellent in cosmetic sustainability and storage stability that can improve such undesirable feelings of use as insufficient spreadability and stickiness, improve the solubility to not only a non-polar oil such as a silicone oil and a light liquid paraffin, but also a polar oil such as a UV-absorber, an ester oil, and a natural animal and vegetable oil, provides non-stickiness with a cosmetic containing the polar oil, and prevent adhesion of the cosmetic to clothes (secondary adhesion).
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: May 5, 2015
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventor: Masanao Kamei
  • Publication number: 20150119553
    Abstract: Compounds are disclosed that are useful for noninvasive imaging in the near-infrared spectral range.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 30, 2015
    Inventors: Xinshe Xu, Daniel R. Draney, Lael Cheung
  • Publication number: 20150119354
    Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Inventors: Daniel Evan Kahne, Suzanne Walker Kahne, Hirokazu Tsukamoto
  • Publication number: 20150119567
    Abstract: This invention provides low molecular weight lipid-GAG and phospholipids-GAG conjugates and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 30, 2015
    Inventors: SAUL YEDGAR, YUVAL COHEN, JOSEPH V BONDI
  • Publication number: 20150119360
    Abstract: The present invention provides a growth promoting composition capable of promoting growth of a microorganism belonging to the genus Bifidobacterium living in the intestine of mammals such as human and the like. According to the present invention, a composition for promoting growth of a microorganism belonging to the genus Bifidobacterium, comprising one or more kinds selected from the group consisting of Lacto-N-tetraose, Lacto-N-neotetraose and derivatives thereof can be provided. The aforementioned growth promoting composition is suitable for promoting growth of the aforementioned microorganism in the intestine by oral administration to, particularly, a human adult.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 30, 2015
    Inventors: Kenji Yamamoto, Satoshi Koizumi
  • Publication number: 20150118322
    Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 30, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU
  • Publication number: 20150105337
    Abstract: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Elizabeth Marie Nolan, Tengfei Zheng, Phoom Chairatana
  • Publication number: 20150104509
    Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventor: Jeffrey Haley
  • Publication number: 20150104643
    Abstract: The invention relates to a crosslinked hyaluronan derivative in the form of a hydrogel or microfibers, and to a method of preparation thereof, consisting in a C—C coupling reaction. The C—C coupling reaction is performed via reaction of a hyaluronan derivative carrying a terminal aryl-halide and/or aryl-borate group, and a hyaluronan derivative carrying an alkenyl or alkynyl group, in water, phosphates buffer or a mixture of an organic acid and an alcohol, and in the presence of a palladium active catalyst. The palladium active catalyst may be e.g. a complex of palladium (II) acetate and an inorganic or organic base, or a complex of palladium (II) and 2-amino-4,6-dihydroxypyrimidine.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 16, 2015
    Inventors: Gloria Huerta-Angeles, Zuzana Jouklova, Eva Prikopova, Vladimir Velebny
  • Publication number: 20150094280
    Abstract: The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 10, 2014
    Publication date: April 2, 2015
    Applicant: SEIKAGAKU CORPORATION
    Inventor: Kenji MIYAMOTO
  • Patent number: 8993536
    Abstract: A low-molecular-weight polysulfated hyaluronic acid derivative useful for treatment of an allergic disease. An agent for treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); wherein n represents a number of 0 to 15; R's each independently represent a hydrogen atom or an SO3H group etc.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 31, 2015
    Assignees: Otsuka Chemical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazuaki Kakehi, Hiroaki Asai, Naohiro Hayashi, Satoshi Shimizu, Fumitaka Goto, Yasuo Koga, Takahiro Tomoyasu, Takao Taki, Yusuke Kato, Satoru Nakazato, Junji Takaba, Atsushi Azuma, Wakako Hirano, Kazunari Izumi, Minoru Kashimoto, Yoko Sakamoto, Takashi Hayashi, Masaru Nishida
  • Patent number: 8993740
    Abstract: The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and the use thereof in pharmaceutical or nutritional compositions.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: March 31, 2015
    Assignee: Glycom A/S
    Inventors: István Bajza, Gyula Dekany, Károly Ágoston, Ignacio Figuero-Pérez, Julien Boutet, Markus Hederos, Ferenc Horváth, Piroska Kovács-Pénzes, Lars Kröger, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas, Péter Trinka, László Kalmár, Irme Kovács, Sándor Demkó, Ágnes Ágoston, Christian Risinger
  • Publication number: 20150087615
    Abstract: Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.
    Type: Application
    Filed: April 18, 2014
    Publication date: March 26, 2015
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Shamgar BEN-ELIYAHU, Pini MATZNER, Steven G. REED
  • Patent number: 8987232
    Abstract: Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier, and a food comprising N-acetyl-D-mannosamine added thereto.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: March 24, 2015
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kunio Shiota, Masayoshi Kuwahara, Takefumi Kikusui, Shintaro Yagi
  • Publication number: 20150080333
    Abstract: Hyaluronic acid particles and their use in biomedical applications are provided. In one embodiment, an HA particle comprising a plurality of free polymer chains extending from a surface of the particle such that the polymer chains are capable of association with polymers or with polymer chains on a surface of other particles is provided.
    Type: Application
    Filed: July 18, 2014
    Publication date: March 19, 2015
    Inventors: Cory Berkland, Amir Fakhari
  • Publication number: 20150065446
    Abstract: The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (HA), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the CD44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug.
    Type: Application
    Filed: June 19, 2014
    Publication date: March 5, 2015
    Inventor: Hua-Yang LIN
  • Publication number: 20150065701
    Abstract: An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: ALLERGAN INDUSTRIE SAS
    Inventor: Pierre F. Lebreton
  • Patent number: 8962822
    Abstract: The present invention provides a modified polyuronic acid represented by formula (1) or a salt thereof which is excellent in surface activity: wherein R1 is a hydrogen atom, a hydrocarbon group having 1 to 40 carbon atoms or the like; X is an oxygen atom, a sulfur atom or a —NH— group, with the proviso that a ratio value of [m/(m+n)] is from 0.3 to 1.0, and a plurality of the R1 groups being present in a molecule of the modified polyuronic acid or the salt thereof may be the same or different from each other but all of the R1 groups are not hydrogen atoms at the same time.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: February 24, 2015
    Assignee: Kao Corporation
    Inventors: Kouji Ohsaki, Kazuaki Sato, Yuri Okutani
  • Patent number: 8952140
    Abstract: A compound having a structure expressed by the following General Formula (1) or a salt thereof where “R” denotes a hydrogen atom or an alkyl group.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: February 10, 2015
    Assignee: Microbial Chemistry Research Foundation
    Inventor: Shigehiro Tohyama
  • Publication number: 20150038693
    Abstract: The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.
    Type: Application
    Filed: August 15, 2014
    Publication date: February 5, 2015
    Applicant: ULTRAGENYX PHARMACEUTICAL INC.
    Inventors: Emil KAKKIS, Steven JUNGLES, He ZHAO
  • Patent number: 8945512
    Abstract: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a paramagnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium (111), thulium (III), ytterbium (III) and europium (111).
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: February 3, 2015
    Assignee: Bracco Imaging SpA
    Inventors: Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Giovanni Battista Giovenzana
  • Patent number: 8946191
    Abstract: Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: February 3, 2015
    Assignee: The Johns Hopkins University
    Inventors: Jennifer H. Elisseeff, Iossif A. Strehin
  • Patent number: 8946394
    Abstract: The present invention relates to a conjugate of acetylated biocompatible polysaccharide and phthalocyanine-based compound for photodynamic diagnosis or therapy in which biocompatible polysaccharide is acetylated and a phthalocyanine-based compound is bound to the acetylated polysaccharide. The conjugate for photodynamic diagnosis or therapy according to the present invention is characterized in that the polysaccharide is acetylated to improve solubility in a solvent and thus enable various chemical modifications, and the conjugate may specifically target tumor cells, has superior cancer cell selecting and accumulating capacity, and has excellent effects of killing cancer cells when near infrared ray is irradiated. The conjugate of the present invention may not show cytotoxicity for cells other than cancer cells even when near infrared ray is irradiated, and thus exhibits superior in vivo stability, and therefore, may be valuably used in disease diagnosis or therapy using photodynamics.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: February 3, 2015
    Assignee: Panaxem Co., Ltd.
    Inventors: Kun Na, Fang Yuan Li, Byoung Chan Bae
  • Patent number: 8946405
    Abstract: The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: February 3, 2015
    Assignee: Prolynx LLC
    Inventors: Gary Ashley, Daniel V. Santi
  • Patent number: 8940859
    Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 27, 2015
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan Boons, Jun Guo, Xinghai Ning, Margaretha Wolfert
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20150025233
    Abstract: This invention provides compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a polymer; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 22, 2015
    Inventor: Saul YEDGAR